



Date 19 December 2016

ASX: NOX

Noxopharm Limited

ABN 50 608 966 123

Registered Office:

Suite 1 Level 6
50 Queen St
Melbourne VIC 3000
Australia

Board of Directors

Mr Peter Marks

Chairman
Non-Executive
Director

Dr Graham Kelly

Chief Executive Officer
Managing Director

Dr Ian Dixon

Non-Executive
Director

MARKET CAPITALISATION

The Company wishes to advise shareholders that the \$50 million market capitalisation performance criteria has been satisfied.

Having achieved the milestone the company has converted performance shares into 10m unlisted ordinary shares, subject to escrow until August 2018.

The updated issued capital of the company is as follows:

		Unlisted	Listed
Listed Fully Paid Ordinary Shares			33,560,000
Unlisted Ordinary shares	Subject to escrow until 08 Jan 2017	464,750	
Unlisted Ordinary shares	Subject to escrow until 01 Apr 2017	4,261,214	
Unlisted Ordinary shares	Subject to escrow until 09 Aug 2018	46,885,465	
Unlisted Options \$0.30 Expiry 28/02/21	Subject to escrow until 09 Aug 2018	18,950,358	
Unlisted Options \$0.30 Expiry 28/02/21	Subject to escrow until 08 Jan 2017	357,500	
Unlisted Options \$0.30 Expiry 28/02/21	Subject to escrow until 01 Apr 2017	3,277,858	

Listed Shares: 33,560,000

Unlisted Shares: 51,611,429

Unlisted Options: 22,585,716

Phillip Hains
Company Secretary

About The Blood-Brain Barrier

The blood-brain barrier exists in the blood vessels in the brain, where the endothelial cells lining the blood vessels are more tightly joined than in the rest of the body, joined by brain cells known as glial cells that control the inflow of compounds into the brain. Together these two layers ensure that passive diffusion of compounds into the brain is limited to water, some gases and a small number of compounds. Everything else, including drugs, is subject to active transport mechanisms which are highly selective. Some 98% of human drugs fail to cross the blood-brain barrier because of the absence of active transporters specific for those drugs.

About Noxopharm

Noxopharm is an Australian drug development company with offices in Melbourne and Sydney. The Company has a primary focus on the development of drugs to address the problem of drug-resistance in cancer cells, the major hurdle facing improved survival prospects for cancer patients. NOX66 is the first pipeline product, with later generation drug candidates under development in an R&D program.

About NOX66

NOX66 is an innovative dosage formulation of the experimental anti-cancer drug, idronoxil, developed specifically to protect idronoxil from being inactivated in the human body by Phase 2 metabolism. Its purpose is to ensure that most idronoxil administered remains in the body in an active form. Idronoxil works by cancelling pro-survival mechanisms in cancer cells regulated by sphingosine-1-phosphate, a key pro-survival mechanism that allows cancer cells to resist the killing effects of chemotherapies and radiotherapy.

INVESTOR AND MEDIA ENQUIRIES:

E: info@noxopharm.com

Prue Kelly

T: + 61 2 9144 2223

Forward Looking Statements

This announcement may contain forward-looking statements. You can identify these statements by the fact they use words such as “aim”, “anticipate”, “assume”, “believe”, “continue”, “could”, “estimate”, “expect”, “intend”, “may”, “plan”, “predict”, “project”, “plan”, “should”, “target”, “will” or “would” or the negative of such terms or other similar expressions. Forward-looking statements are based on estimates, projections and assumptions made by Noxopharm about circumstances and events that have not yet taken place. Although Noxopharm believes the forward-looking statements to be reasonable, they are not certain. Forward-looking statements involve known and unknown risks, uncertainties and other factors that are in some cases beyond the Company’s control that could cause the actual results, performance or achievements to differ materially from those expressed or implied by the forward-looking statement. No representation, warranty or assurance (express or implied) is given or made by Noxopharm that the forward-looking statements contained in this announcement are accurate and undue reliance should not be placed upon such statements.